Acute Hepatic Porphyria (AHP)

International Porphyrias Symposium (IPS) 2025

Congress Details

9-12 October, 2025 | USA

Washington, D.C.

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to givosiran▼. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Congress Materials

Presentation Type

Poster

Location

Washington, D.C.

Title

Chronic symptoms reported by patients with acute hepatic porphyria in the POWER study in a subgroup analysis of non-recurrent patients

Presentation Type

Poster

Location

Washington, D.C.

Title

Annualised attack rate reductions versus historical data and hemin use of patients with acute hepatic porphyria in phase 3 ENVISION trial who were not attack-free after 6 months of givosiran treatment

Access Prescribing Information

Presentation Type

Poster

Location

Washington, D.C.

Title

ENVISION study EQ-5D analysis to assess relationship between annualised attack rate with expanded criteria and chronic symptoms in patients with acute hepatic porphyria